Document is current
Any future updates will be listed below
-
Authors
Yang, Wuxia
Liu, Yang
Kang, Huiying
Wang, Zhen
Song, Yanqi
Liu, Baoshan
Wang, Aidi
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82374354)
- License Information
-
More Information
Article History
Received: 31 October 2025
Accepted: 4 February 2026
First Online: 16 February 2026
Declarations
:
: All animal experiments were conducted in accordance with the ARRIVE 2.0 guidelines and approved by the Ethics Committee of the Tianjin Medical University General Hospital (Exploration of the Mechanism by Which the Blood-Permeable Active Components of the Ningxue Shengban Decoction Regulate T-Cell Immune Tolerance Through BMSC-Derived Exosomal miR-223 in the Treatment of ITP; Approval No: IRB2023-DWFL-095; Date of approval: 2023-02-24).
: The authors declare no competing interests.
